Previous 10 | Next 10 |
When Takeda Pharmaceutical ( TAK ) said that it would develop a coronavirus vaccine, the stock briefly rose. But the real driver for the company's growth will not come from this market. Currently, the main players in the coronavirus treatment will earn almost nothing. Gilead Sciences (...
Johnson & Johnson (NYSE: JNJ ) says it is abandoning plans to buy Takeda Pharmaceutical's (NYSE: TAK ) TachoSil surgical patch product due to regulatory issues. More news on: Johnson & Johnson, Takeda Pharmaceutical Company Limited, Healthcare stocks news, Read more...
Is now a good time to buy stocks? Given that we have yet to see the full economic impact of the COVID-19 pandemic -- and that equity markets may see even more turbulent days ahead -- some might choose to refrain from purchasing stocks altogether. However, long-term investors may want to take t...
CSL Behring (OTC: CSLLY) and Takeda Pharmaceutical (NYSE: TAK) are joining forces with four other companies -- Biotest, Bio Products Laboratory, LFB, and Octapharma -- to develop a plasma-derived antibody treatment they hope will prove effective against COVID-19, the disease caused ...
Help is on the way. In the midst of a societal upheaval resulting from the novel coronavirus and the disease that it causes, COVID-19, there are many efforts in progress to find solutions to slow the spread of the disease and treat those who already have it. These efforts include those from gov...
– Approval Based on Positive Results from the Phase 3 ALTA-1L Trial Showing ALUNBRIG Demonstrated Superior Overall and Intracranial Effectiveness over Crizotinib in the First-line Setting – – Expanded Indication Provides Additional First-Line Treatment Option fo...
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19 Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and T...
The Food and Drug Administration is encouraging people who have recovered from COVID-19 , the disease caused by the novel coronavirus, to donate their blood plasma, which can be processed into an antibody product that can treat current patients. Based on the medical community's experience with...
Quick Take Keros Therapeutics ( KROS ) intends to raise $75 million from the sale of its common stock, per an amended S-1/A regulatory filing . The company is advancing a pipeline of drug treatment candidates for hematological and musculoskeletal diseases. KROS is entering Phase 2 trial...
Policy further strengthens Takeda’s commitment to best-in-class corporate governance Takeda Pharmaceutical Company Limited ( TOKYO:4502/NYSE:TAK ) (“Takeda”) today announced that its Board of Directors approved an executive compensation recoupment policy (“...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection Canada NewsWire The Letter of Intent is an important ste...
Wednesday, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine received World Health Organization’s (WHO) preq...
Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill. Takeda’s presentations will spa...